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photericin B was continued. There 
was minimal progression of the ul-
cer over the next 2 days, but by day 
21 there was recovery of white cells 
(total white cells, 2.9×109/L). Soon, 
fever resolved and the lesion started 
healing; by day 37 only a 2-cm in-
duration was visible. The patient 
continued on daily amphotericin B 
for another 4 weeks after which it 
was administered on an alternate 
day schedule during the consolida-
tion cycles (high-dose cytarabine). 
Currently, 6 months after therapy 
the patient continues to be in remis-
sion and has no evident lesion over 
the vulva.
Cutaneous (10% to 19 % of all 
mucormycosis) presentation of mu-
cormycosis may have a favorable 
outcome with early detection and 
treatment but advanced lesions have 
up to 80% mortality.2 Definitive 
treatment includes aggressive surgi-
cal debridement, early use of effec-
tive antifungal therapy, and correc-
Figure 1A. Ulcerated vulval ulcer on day 18. 
Figure 1B. Organisms with broad nonseptate hyphae in necrotic 
material (He stain ×40).
Figure 1C. The broad nonseptate hyphae of mucor have stained 
black (GmS staining ×40).
Figure 1D. invasion of artery by mucor (He stain ×40).
tion of predisposing factors. Very 
few cases of vulvar mucormycosis 
has been reported.3 
Surgical debridement is often 
difficult in patients with acute leu-
kemia due to combination of fac-
tors like ongoing sepsis and very 
low blood counts, but earlier reports 
have documented successful treat-
ment of mucormycosis in this setting 
with the use of antifungal alone.4,5 In 
our case, early detection, institution 
of amphotericin B, and recovery of 
neutrophils within a week of onset 
of the lesion contributed to the suc-
cessful and complete resolution of 
mucormycosis without resorting to 
aggressive and potentially mutilat-
ing surgical debridement. 
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